To evaluate the success of Ahmed Glaucoma Valve Implantation (AGV) in patients with glaucoma secondary to Iridocorneal Endothelial (ICE) syndrome.
This retrospective study included 18 eyes of 18 patients with ICE syndrome and glaucoma who had undergone AGV implantation at our institute between January 2008 and April 2019. The primary outcome was success of AGV, defined as intraocular pressure (IOP) ≥6▒mmHg and ≤21▒mmHg with or without topical anti-glaucoma medication (AGM). Failure was defined as IOP <6 or >21▒mmHg/need for oral AGM/need for additional glaucoma surgery or loss of light perception due to a surgical complication. Corneal clarity and graft survival in these eyes post-AGV was the secondary outcome measure.
The median (interquartile range or IQR) follow-up was at 20.61 (3.9-57) months. Of the 18 eyes, 14 (77.8%) had adequate IOP control with or without AGMs. Postoperatively, the mean (±Standard deviation) IOP significantly reduced from 29.7(±10) mm Hg to 16(±3.8) mm Hg and the number of AGMs reduced significantly from a mean of 3.6 (±1) to 1.7 (±0.9). The probability of AGV success was 92.3±7.4%, 66.1±11.0% and 50.5%±17.3% at 1, 3 and 4 years respectively. All four failures were due to uncontrolled IOP and needed either oral AGM or additional surgery for IOP control. At the last follow-up visit, 16 eyes had clear cornea, and two eyes had pre-existing corneal scar (eccentric) that persisted after AGV implantation.
Ahmed Glaucoma Valve implant was reasonably successful for IOP control in glaucoma secondary to ICE syndrome with a few common but manageable corneal complications.

Author